Published in final edited form as:

Cell Mol Life Sci. 2014 April ; 71(7): 1245–1263. doi:10.1007/s00018-013-1491-1.

Mechanisms of cellular invasion by intracellular parasites

Dawn M. Walker^{1,5}, Steve Oghumu², Gaurav Gupta², Bradford S. McGwire^{1,3,5,+}, Mark E. Drew^{1,5,+}, and Abhay R. Satoskar^{2,4,5,*,+}

¹Department of Microbial Infection and Immunity, The Ohio State University and Wexner Medical Center, Columbus, Ohio 43210.

²Department of Pathology, The Ohio State University and Wexner Medical Center, Columbus, Ohio 43210.

³Division of Infectious Diseases-Department of Medicine, The Ohio State University and Wexner Medical Center, Columbus, Ohio 43210.

⁴Department of Microbiology, The Ohio State University and Wexner Medical Center, Columbus, Ohio 43210.

⁵Center for Microbial Interface Biology, The Ohio State University and Wexner Medical Center, Columbus, Ohio 43210.

Keywords

Leishmaniasis; American trypanosomiasis; Chagas disease; toxoplasmosis; Malaria; *Leishmania*; *Trypanosoma cruzi*; *Toxoplasma gondii*; *Plasmodium*; invasion

Numerous disease-causing parasites must invade host cells to prosper. Collectively, such pathogens are responsible for a staggering amount of human sickness and death throughout the world. Leishmaniasis, Chagas disease, toxoplasmosis, and malaria are neglected diseases and therefore are linked to socio-economical and geographical factors, affecting well-over half the world's population.

Such obligate intracellular parasites have co-evolved with humans to establish a complexity of specific molecular parasite-host cell interactions, forming the basis of the parasite's cellular tropism. They make use of such interactions to invade host cells as a means to migrate through various tissues, to evade the host immune system, and to undergo intracellular replication. These cellular migration and invasion events are absolutely essential for the completion of the lifecycles of these parasites and lead to their for disease pathogenesis.

This review is an overview of the molecular mechanisms of protozoan parasite invasion of host cells and discussion of therapeutic strategies, which could be developed by targeting these invasion pathways. Specifically, we focus on four species of protozoan parasites

*Correspondence: Abhay R. Satoskar MD, PhD, Department of Pathology, 129 Hamilton Hall, 1645 Neil Avenue, Columbus, Ohio 43210, USA. Abhay.satoskar@osumc.edu.

⁺Share equal contribution in authorship.

Leishmania, *Trypanosoma cruzi*, *Plasmodium* and *Toxoplasma*, which are responsible for significant morbidity and mortality.

Mechanisms of host cell invasion in *Leishmania*

i. Introduction

Leishmania are obligate intracellular protozoa that infect mononuclear phagocytes. The parasites exist in two morphological forms, as an intracellular aflagellated amastigote in the vertebrate hosts, such as humans, dogs, lizards or rodents, and as a motile flagellated promastigote in the invertebrate sand fly vector. Six major *Leishmania* species (*L. tropica*, *L. major*, *L. donovani*, *L. infantum*, *L. braziliensis*, and *L. mexicana*) cause the three main forms of the disease in humans, dermal cutaneous leishmaniasis, visceral leishmaniasis (VL), and muco-cutaneous leishmaniasis. The form and severity of the disease greatly depend on the infecting *Leishmania* species and the immune status of the host[1].

ii. Life cycle

Leishmania amastigotes are taken up by a female sand fly from an infected vertebrate host during a blood meal. Within the gut of the sand fly, *Leishmania* amastigotes transform via intermediate non-infective procyclic promastigotes into infective metacyclic promastigotes[2]. Infective metacyclic promastigotes are introduced intradermally into the pool of blood of the vertebrate host by the feeding infected sand fly[3]. Within a short span of time, neutrophils are recruited to site of sand fly bite, where they engulf the promastigotes providing them with temporary shelter[4]. Infected neutrophils or free parasites are then taken up by professional phagocytes (dendritic cells and macrophages) which migrate away from the site of the sand fly inoculation site[5]. *Leishmania* promastigotes survive in the parasitophorous vacuoles where they transform into amastigotes and replicate, eventually overburdening the infected cell leading to rupture. Extracellular amastigotes re-infect local phagocytes leading to subsequent cycles of infection. The transmission cycle is complete when infected phagocytes or extracellular parasites are taken up by feeding sandflies. Amastigotes then transform into promastigotes in the sand fly midgut and then further differentiate to become infective metacyclic promastigotes, which are able to infect a new vertebrate host[6]. *Leishmania* can also be transmitted through blood transfusion from previously infected to naïve human hosts[7, 8].

iii. Mediated uptake by host cells at the site of sand fly inoculation

When an infected sand fly releases *Leishmania* promastigotes into the skin, they evade immediate host immune response and destruction by seeking refuge in different types of host cell, which includes dermal macrophages (Fig. 1), fibroblasts, keratinocytes and dendritic cells (DCs). Metacyclic promastigotes evade immediate destruction by deactivating the host's complement system[9, 10]. In particular, lipophosphoglycan (LPG), which is highly expressed on the surface of metacyclic promastigotes, interferes with the insertion of membrane attack complex[11] and promastigote specific kinases deactivate the classical and alternative complement pathway by phosphorylating complement proteins[12]. Furthermore, the surface-membrane metalloprotease, glycoprotein 63 (known as gp63, leishmanolysin, or major surface protease), cleaves C3b attached to its surface, to an

inactive form, C3bi, which facilitates the complement receptor 3 (CR3) mediated entry into the host cells[13]. *Leishmania* promastigotes gain entry into the dermal macrophages by utilizing the host CR3, which prevents the parasites from being killed by circulating phagocytes and nonimmune serum. Additionally, in dermal macrophages, which lack the respiratory burst machinery, promastigotes have enhanced ability to transform into and multiply as amastigotes compared to other macrophage populations[14]. Similarly, both *Leishmania* promastigotes and amastigotes are actively ingested by the skin fibroblasts[15]. These cells provide a safe environment for *Leishmania* for up to 7 days post-infection, as they produce low levels of nitric oxide even in the presence of lipopolysaccharide and interferon- γ , compared to macrophages[15]. The saliva of sand flies has been shown to have hemostatic and immunomodulatory effects in the host which affect the infectivity and pathogenesis of *Leishmania*[16]. While many of these effects are common to the saliva from Old (*Phlebotomus spp.*) and New (*Lutzomyia spp.*) World sand flies, there also some effects that are different. Sand fly saliva contains a multitude of components, the most well described is the vasodilator protein called Maxadilan[17, 18]. Sand fly saliva increases the migration of inflammatory cells to the site of deposition, enhancing the interaction of *Leishmania* with potential host cells[19]. The saliva from *Lutzomyia longipalpis* and Maxadilan alone decrease TNF- α , IL-10 and increase IL-6, IL-8 and IL-12 production in LPS stimulated human macrophages[20]. Maxadilan diminishes DTH responses in mice and inhibits T-cell activation[20–22], and *Phlebotomus* saliva upregulates Th2 responses and down-regulates Th1 responses in *L. major* infection[23]. The saliva of *Phlebotomus papatasi* down-regulates NO production in LPS- or IFN- γ activated macrophages[23, 24]. Repeat exposure of hosts to sand fly saliva induced antibody formation and cell-mediated responses to saliva proteins. Interestingly, pre-exposure to sand fly saliva has been shown to be protective to subsequent leishmania infection[25, 26], bringing forth the possibility is using saliva components as a vaccine[27–31]. Work is ongoing in order to understand how the responses to saliva protect against leishmaniasis or if the results of these studies in mice are applicable to humans[32].

Keratinocytes are epithelial cells in the skin that form an important initial barrier between the host and the environment. The cellular interaction between keratinocytes and *Leishmania* is critical in delivering the initial triggers for Th-cell differentiation, although these are not target cells for parasite entry. Moreover, early cytokine expression of IL-1 β , osteopontin, IL-12, IL-4 and IL-6 occurs in the keratinocytes of parasite-resistant mice strains following inoculation of *Leishmania* promastigotes. Among these cytokines, IL-6 and IL-4 from epidermal keratinocytes are essential for resistance and generation of protective Th1 immunity[33]. On the other hand, DCs present in the epidermis are highly motile and capable of crawling between interstitial tissue spaces serving as efficient pathogen sensors[34]. These cells internalize *Leishmania* and transport them to lymph nodes for priming of *Leishmania* specific T cells[35]. Interestingly, mice depleted of epidermal DCs had smaller lesions and reduced number of disease promoting T regulatory cells highlighting the role of DCs in promoting host susceptibility[36].

iv. Mediated uptake by neutrophils

Neutrophils are the first cells to arrive at the site of infection within a few minutes of a sand fly bite[37]. This early recruitment of neutrophils might depend on specific cues provided by the release of alarmins (signal for tissue damage), chemokines and cytokines[38, 39]. Neutrophils are crucial cells for early defense against infections as they can kill obligate intracellular pathogens via reactive oxygen species (ROS) [40, 41], neutrophil elastase (NE) or neutrophil extracellular traps (NET)[42]. However, once phagocytic killing has been evaded or silenced, neutrophils can serve as host cells for *Leishmania* promastigotes[37]. Human neutrophils can readily phagocytose *L. major* promastigotes but amastigote recognition or uptake has not been detected by extracellular neutrophils[43]. Lipophosphoglycan and tartrate-resistant acid phosphatase present on the cell surface of *Leishmania* promastigotes inhibits lysosome fusion and the respiratory burst and superoxide anion production in neutrophils[44–46]. *Leishmania* promastigotes release chemotactic lipid *Leishmania* chemotactic factor (LCF), which attracts neutrophils[47] and interacts with Lipoxin A4 receptors (ALX) which deactivates the neutrophil oxidative burst[48]. Neutral elastase, a serine peptidase released by neutrophils, is deactivated by an inhibitor of serine peptidase present in *Leishmania*, which is crucial for intracellular parasite survival [49]. Moreover, virulent inoculum of *Leishmania* promastigotes contains a large subpopulation of apoptotic parasites which bind to host annexin A5, which induces TGF- β and consequently mediates the silencing of phagocytes and survival of the viable subpopulation[50, 51].

Promastigotes can effectively modulate the short lifespan of neutrophils by delaying or accelerating apoptosis to their advantage. Neutrophils from human blood or murine peritoneal cavity have delayed apoptosis upon *Leishmania* infection[50–52]. On the contrary, neutrophils from infected dermis exhibit a marked increase in apoptosis, indicated by the enhanced expression of phosphatidylserine (PS). Interestingly, this increase in PS expression marks the infected neutrophils to be phagocytosed by dermal dendritic cells[53]. Similarly, infected neutrophils are also phagocytosed by macrophages indirectly delivering promastigotes forming the basis for the Trojan horse model of macrophage infection[51]. However, recent *in vivo* studies have shown that neutrophils do not directly transfer their parasites to the macrophages. Instead, the apoptotic neutrophils lyse releasing the apoptotic and viable promastigotes, which are then engulfed by the macrophages[37, 53].

v. Mediated uptake by Macrophages

Macrophages serve as one of the critical host cells for *Leishmania* parasites and it is therein where parasites undergo amastigotes transformation and replicate and deactivate the microbicidal machinery of the host cell. The C3bi (generated by C3b proteolysis by gp63) opsonized metacyclic promastigotes bind to macrophage receptor CR3 facilitating silent entry into the macrophages[13, 54]. Additionally, gp63 binds directly to fibronectin receptors through at least two domain[55, 56] and may also utilize this receptor by forming a bridge between gp63 bound fibronectin[57]. High-mannose type glycans on the surface of promastigotes also facilitate parasite binding through mannose-fucose receptors[58]. Gp63 may also bind directly to CR3 to promote invasion[59]. After initial attachment, *Leishmania* promastigotes initiate caveolae-dependent phagocytosis for entering host macrophages[43]. *Leishmania* LPG is inserted into phagosome cholesterol-rich lipid microdomains which

causes exclusion of the exocytosis regulator, synaptotagmin V, which prevents the acquisition of cathepsin D and the vesicular proton-ATPase, in the newly formed *Leishmania*-containing vacuoles (Fig. 1). This creates an intracellular phagosomal niche that fails to acidify and trigger microbicidal machinery, providing sufficient time for promastigotes to differentiate into amastigotes[60]. Furthermore, vacuoles containing promastigotes interact poorly with late endosomes and lysosomes, as observed by the delayed recruitment of LAMP-1 and Rab7. These events result in the delay of phagosome maturation which interferes with the recruitment of signal transducers and vesicle trafficking to developing phagosomes[61, 62]. This is characterized by the formation of F-actin coat around the phagosome due to LPG-mediated deactivation of protein kinase C (PKC) α [63] and abnormal retention of actin polymerization machinery (Arp2/3, Wiskott Aldrich Syndrome Protein, myosin and α -actinin) and Cdc42[64]. This also leads to the LPG-dependent exclusion of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase cytosolic components, p47^{phox} and p67^{phox}, from the promastigote containing phagosome resulting in deactivation of ROS generation[65]. As promastigotes transform into amastigotes, the parasitophorous vacuoles become acidic (pH 4.7–5.2) [66, 67] and acquire lysosomal hydrolases and late endosomal/lysosomal proteins such as Rab7 and LAMP-1[67]. Amastigotes multiply within these phagolysosomes until being released from ruptured macrophages and then enter neighboring macrophages through a non-caveolae pathway after ligating Fc- γ and PS receptors[1]. Amastigotes survive in phagolysosomes using several strategies that include: 1) deactivation of the ROS generation machinery[68, 69]; 2) attenuation of the PKC activity[70]; 3) suppression of STAT1 signaling[71]; 4) dysregulation of JAK/STAT signaling by depleting membrane cholesterol[72]; 5) activation of *Leishmania* specific ectoprotein phosphatases, cysteine proteinases or host cellular phosphotyrosine phosphatases or by inducing ceramide generation[73–77] 6) interference with the strength of CD40 cross-linking[78, 79]; 7) inhibition of mTOR complex 1 along with concomitant activation of translational repressor 4E-BP1 which promotes *Leishmania* proliferation[80]. In addition, the phagolysosomes containing *Leishmania* are enlarged due to increased expression of lysosomal trafficking regulator gene (*LYST/Beige*) that protects the parasites from oxidative damage by diluting the microbicidal effects of nitric oxide[81].

Furthermore, *Leishmania* also interferes with the strength of CD40 cross-linking or reciprocally activates MAPK phosphatases (MKP), MKP-1 and MKP-3 resulting in antagonistic regulation of ERK1/2 and p38MAPK which governs the production of IL-10 and IL-12 by *Leishmania*-infected macrophages[78, 79].

vi. Therapeutic considerations

The current anti-leishmanial drugs antimonials, amphotericin B, pentamidine, and miltefosine have limited therapeutic application due to toxicity and increasing multiple drug resistance. Novel therapeutic approaches are needed and those based on thwarting the mechanisms crucial for cellular invasion by *Leishmania* may hold promising results. Targeting MAPK signaling pathway using the specific MKP-1 inhibitor, triptolide, could be an effective therapeutic option for controlling *L. major* infection[79]. Similarly, AS-605240, a PI3K γ inhibitor, is another promising therapeutic candidate as it confers resistance against *L. mexicana* infection and showed similar protection as sodium stibogluconate[82].

Furthermore, cysteine proteases, important for intracellular survival of *Leishmania* amastigotes, are targeted by cystatin, a natural cysteine protease inhibitor, for curing experimental VL and could be developed as potential therapeutic candidate[83, 84]. Since *Leishmania* depletes membrane cholesterol and disrupts lipid rafts in host macrophages, therapies based on restoration of cholesterol levels[72, 85, 86] and raft-associated proteins[87, 88] are other promising strategies.

Mechanisms of host cell invasion by *Trypanosoma cruzi*

i. Introduction

The lifecycle of *Trypanosoma cruzi* was first described in the early 1900's by the Brazilian physician Carlos Chagas, who while working on malaria, suspected that insects infesting local rural dwellings transmitted human disease. Upon dissection he found motile flagellated parasites within the gastrointestinal tracts of these triatomine insects (family *Reduviidae*). He named the parasite after his mentor Prof. Oswaldo Cruz and determined that these were infective to mammals through experimental infection of monkeys, and further established they caused human disease by finding the parasite in the blood and tissues of acutely and chronically infected patients. In doing so, Chagas has been the only scientist that has completely described the epidemiology, clinical syndrome, etiology, vector and complete lifecycle of a microbial agent. Named after him, Chagas disease (also known as American trypanosomiasis), describes the clinical syndromes caused by infection with *Trypanosoma cruzi*[89].

ii. Life cycle of *Trypanosoma cruzi*

The life cycle of *Trypanosoma cruzi* is complex and interesting. Transmission of *T. cruzi* occurs mainly by deposition of infective metacyclic trypomastigotes (MT) present in the urine and feces of hematophagous bugs from the family *Reduviidae*, of the genera *Triatoma*, *Rhodnius* and *Panstrongylus*. The development of replicative non-infective epimastigote forms into infective MTs during their transit in the insect gastrointestinal tract is essential to the transmission to human hosts. Once MTs are deposited in the feeding wound they can invade nucleated hosts cells or be engulfed by professional phagocytes (macrophages and dendritic cells)[90]. Human infection by the oral ingestion also occurs through the stomach epithelial invasion of MTs present in insect contaminated preparations of fruit juice[91–95]. After MT host cell infection, parasites are initially housed in parasitophorous vacuoles but then escape into the host cell cytoplasm and differentiate into aflagellated amastigotes. Amastigotes replicate in the cytoplasm until they are triggered to differentiate into motile flagellated trypomastigotes, which escape host cells and disseminate in the blood and lymph. The triggers for intracellular differentiation of amastigotes into trypomastigotes are unknown. Blood-stream trypomastigotes lead to further infection by binding to and invading nucleated non-phagocytic cells and are also phagocytized by macrophages, both similar to the initiation of infection that occurs by insect-derived MTs. Amastigotes are also infective and can disseminate in infected hosts. The life cycle is complete when trypomastigotes or amastigotes are ingested by reduviid bugs feeding on mammalian hosts, wherein they differentiate back into replicative epimastigotes. The mechanisms by which *T. cruzi* life cycle forms invade human cells are discussed in more detail below. While insect

transmission is the primary mode of parasite acquisition, oral and transplacental routes can also occur and infection through transplanted blood and tissue from chronically infected individuals is increasing worldwide and has prompted expansion of screening practices of donated products[96, 97].

iii. Mechanisms of host cell invasion

T. cruzi can actively invade multiple non-phagocytic cells. The MTs and bloodstream trypomastigotes (also termed tissue-culture derived trypomastigotes, or TCT, produced *in vitro* by cultivation of parasites in tissue culture and provide a model of bloodstream forms) are the main infective forms of the parasite and will be referred to as trypomastigotes collectively throughout the rest of this review unless otherwise specified. Infection by amastigotes can also lead to productive infection although the mode of infection by these forms is not entirely understood. Epimastigotes are also infective *in vitro* but are not widely thought to contribute significantly to natural infection. The process of invasion by trypomastigotes is complex and dynamic and involves the interplay of multiple parasite and host factors. The bulk of studies looking at invasion have been done *in vitro* with a variety of different host cell systems. This is complicated by the fact that different parasite strains infect cells by different mechanisms. Parasites can also infect macrophages by phagocytosis or through parasite invasion, as they do in non-phagocytic cells. There is controversy as to which of these is the main mode of parasite entry, however both are operative simultaneously. The information below provides a general overview of the main concepts concerning *Trypanosoma cruzi* host cell invasion. The readers may want to refer to several excellent and comprehensive reviews by pioneers in this field for further information[98–101].

iv. Non-phagocytic cell infection

In vitro analysis of parasite invasion of non-phagocytic cells has resulted in the definition of several distinct steps (Fig. 2). Trypomastigotes initiate infection by interacting with the host cell surface membrane by way of several parasite surface-membrane protein ligands. The host cell receptors for many of these ligands have not yet been identified. Many members (gp82, gp90, gp85/TS, gp30) of the gp85/trans-sialidase (TS) super-family are implicated in the initiation of infection by trypomastigotes[102, 103]. Gp82, and the related gp30, are MT-specific surface proteins that upon engagement of an unknown receptor(s) mediate bidirectional Ca^{2+} release in both the parasite and host cell[104–106]. On the parasite side, this interaction triggers phospholipase C (PLC) activation generating diacylglycerol (DAG) and inositol triphosphate (IP3) which further activates protein kinase C and release of Ca^{2+} from the endoplasmic reticulum. In host cell targets, PLC is activated which ultimately release Ca^{2+} from intracellular stores via IP3-signaling. Recent data indicates that phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) are also triggered during this process, however the downstream events beyond this are not well elucidated[106]. In some parasite strains which express gp33/50, a mucin-related protein, host cell Ca^{2+} release is triggered leading to invasion similar to but not as robustly as that mediated by gp82[107]. Gp90 expressed in MTs of some parasite strains is a negative regulator of cell invasion and does not trigger Ca^{2+} mobilization or intracellular signaling[107, 108]. Gp82, –30, –90 and –35/50 are expressed to different degrees in

various *T. cruzi* strains which underscores the complex heterogeneity of the mechanisms of parasite invasion[109]. Bloodstream trypomastigotes appear to invade cells in a similar fashion but through a different set of interactions. Host cell PLC activation occurs through triggering of the host bradykinin receptor, in an interesting mechanism in which parasite secrete cruzipain, a cysteine protease, that cleaves host kininogen to liberate bradykinin[110, 111]. Similar to MT invasion, PLC activation generates IP₃, which triggers downstream release of host Ca²⁺. Ca²⁺ release is also mediated by action of a proteolytic cleavage product generated by oligopeptidase B activity on an unknown parasite protein substrate[112–114]. Parasite surface-membrane *trans*-sialidase (TS) promotes invasion of bloodstream forms through transfer of host surface sialic acid residues onto various parasite mucins-proteins, which are a large family of heavily glycosylated GPI-linked surface proteins[115–117]. Engagement of these sialylated parasite proteins trigger host cell signaling via activation in a number of different ways including PI3K/Akt-, MAP-kinase and ERK- pathways[118–120].

Parasite binding of extracellular matrix proteins (ECM) (fibronectin, laminin and collagen) and proteoglycans (heparin, heparin sulfate) is also implicated in invasion[121–124]. The gp85/TS superfamily of proteins been shown to bind multiple ECM components[123]. Also notable is a 60 kDa surface protein, termed Penetrin, that binds heparin and heparin sulfate in a sialic acid-independent manner which promotes invasion[125, 126], and may also associate with ECM components. Recently, homologs of the leishmanial surface protease, gp63, have been described in *T. cruzi*, and it appears as they may be involved in parasite-host cell binding[127, 128], however is it unclear if they are molecularly distinct from Penetrin.

Binding and invasion of host cells by parasites trigger several different, yet overlapping parasite entry pathways. Exploitation each of these is how by *T. cruzi* is such a successful pathogen at infecting multiple cell types. Each of these pathways which culminate in the encasement of parasites within lysosomal-membrane based vacuoles, which are necessary for subsequent events leading to productive infection[129].

In the “lysosomal-dependent pathway”, lysosomes are recruited to the site of parasite binding in a Ca²⁺-dependent manner. The exocytosis of lysosomes occurs by their fusion with the surface membrane abutting the parasite which causes release of acid sphingomyelinase which generates ceramide through cleavage of membrane sphingomyelin[130]. The formation of ceramide in the outer leaflet of the membrane induces endocytosis of the wounded membrane. Parasites take advantage of this by becoming internalized in these lysosomal-based endosomes. This process may require the Ca²⁺-binding protein synaptotagmin VI and is probably powered by kinesin movement on microtubules that requires Ca²⁺-calmodulin[131, 132], both correlating with the necessary role of Ca²⁺ in this process. In the “lysosomal-independent pathway” parasites are initially housed in surface-membrane containing phosphoinositides, which eventually fuse with the lysosomes at later times post-infection[133, 134]. The protein dynamin, a GTPase, that associates with PI3K, may be involved in formation and dynamics of vacuole maturation[135, 136]. Prior to lysosomal fusion parasite entry into cells is reversible and

parasites can escape the host cell. Thus fusion of these plasma membrane-derived vacuoles with lysosomes is a key step that leads to productive infection[137].

A third pathway has been proposed in which parasites exploit the autophagocytic pathway which is operative under starvation conditions[138–140]. In this pathway, parasites invade cells and are initially housed in autophagocytic vacuoles, which eventually fuse with lysosomes to create an acidic autophagolysosomal compartment. These vacuoles are thought to be rich in nutrients for parasite survival and polyamines which promote differentiation of trypomastigotes into amastigotes[141]. Overall, this last model is probably a modified version of the lysosomal-independent pathway specialized for conditions of starvation. The functional significance of actin and whether it is required or deleterious to parasite invasion in these pathways is likely a function of the ligands utilized for entry by different parasite forms[142].

Extracellular amastigotes are also infective to both phagocytic and non-phagocytic cells. Amastigotes of different strains appear to actively invade non-phagocytic host cells through recruitment of actin at the site of parasite attachment[142–144]. *T. cruzi* infection also occurs through the oral route where it has been responsible for several outbreaks[91, 95]. This occurs through parasite contamination of fruit juice (e.g. acai and guava fruit) from crushing of parasitladen triatomines present on berries during processing. Consumption of contaminated juice delivers MTs into the stomach and duodenum where they invade the gastric mucosal lining. Parasite gp82 is a chief ligand for invasion and the proteolytic degradation of the anti-invasive ligand gp90 further facilitates parasite entry[145–147]. Parasite strains not expressing gp82 invade via the related gp30 which also triggers Ca^{2+} signaling. Parasite strains expressing gastric protease-susceptible gp90 are relatively more infective via the oral route than those expressing protease-resistant gp90[148].

v. Phagocytic cell infection

Macrophages are also targets for parasite infection, especially at the initiation of infection when MTs are deposited in the tissue by insects. In addition, amastigotes released from infected cells also infect macrophages. Both stages are taken up by phagocytosis, initially housed in parasitophorous vacuoles, where they can be killed by generation of nitric oxide and peroxynitrite[149–151]. The maturation of parasitophorous vacuoles into phagolysosomes is important for parasite survival, which is required for entry into the host cytoplasm where they avoid exposure from microbicidal radicals. In the cytoplasm parasites differentiate and replicate as they do in non-phagocytic cells. The initial entry of parasites into macrophages is probably by way of both an actin-dependent phagocytic process and an active invasion process similar as those described above in non-phagocytic cells. Recent studies indicate that the integrity of membrane rafts composed of cholesterol, ganglioside GM, flotillin and caveolins are important in trypomastigote and amastigote infection of macrophages[152–154]. It is unclear whether, in the case of macrophages, this affects only active-invasion and/or the phagocytic parasite pathway. However, lipid membrane raft disruption diminishes infection of non-phagocytic cell invasion by trypomastigotes probably by disaggregation of proteins important for signaling pathways that initiate the invasion process.

vi. Therapeutic considerations

The drugs currently used to treat Chagas disease include the nitroheterocyclics compounds benznidazole and nifurtimox, which are indicated in acute and intermediate stage *T. cruzi* infection. The mechanism of action of nifurtimox is not completely understood but is probably due to the induction of oxidative radical formation within the parasite and/or lowering of thiol levels through the production of nitroso-intermediate due to reduction of the nitro-group of the compound by the parasite[155–157]. The action of benznidazole is thought to act by reduction of macromolecule production through interactions of its' nitro-group[158, 159]. The efficacy of these drugs in chronic Chagas disease is somewhat controversial and trials are underway to determine if there is any benefit of treatment at this late stage[160–162]. These drugs are significantly toxic, yet are the mainstay of anti-parasitic therapy because there are no other alternatives approved for human use at present. Inhibitors of cruzipain, an important cysteine protease of *T. cruzi*, are promising candidates for future therapy[163–165]. This protease is essential for viability of all stages of *T. cruzi* and is important as several key steps in the lifecycle, including parasite invasion (see above), cell division and differentiation[166]. Preliminary studies indicate that the vinyl sulfone inhibitor, K11777, is a therapeutic candidate and that other compounds that inhibit this enzyme may find their way into the pipeline of new investigational drugs.

Mechanisms of host cell invasion by Apicomplexan parasites

i. Introduction

Apicomplexan parasites are a unique group of protists united by the presence of an organelle called the apicoplast as well as the apical complex, a structure specifically involved in host cell invasion. Although there are many organisms that fall under the phylum Apicomplexa, this section of the review will focus primarily on *Plasmodium falciparum*, the causative agent of cerebral malaria, with additional discussion of *Toxoplasma gondii* invasion, the causative agent of Toxoplasmosis.

Malaria is an infectious disease that has plagued man for millennia. Despite enormous struggles at prevention and treatment, currently over 250 million cases occur annually, resulting in an estimated 700,000 deaths, mostly African children[167]. Humans get infected with *P. falciparum* when bit by an infected mosquito, as this is the definitive host. The impact of this disease on the at-risk population is staggering and new, targeted approaches to prevent and cure it are desperately needed. *T. gondii* can infect any mammal, with humans being an accidental host. *T. gondii* can only sexually reproduce in the intestines of cats, the parasite's definitive host, making every other host an intermediate host. In the United States over 60 million people carry the parasite but generally only those with compromised immune systems and pregnant women develop symptoms of disease[168]. Humans get infected by ingesting parasite-contaminated food or water or by ingesting infected and undercooked meat.

Although we understand a great deal regarding the biology of the parasites responsible for malaria and toxoplasmosis, it is only relatively recently that many of the molecular mechanisms by which the parasite recognizes and invades or traverses through host cells

have been elucidated. There is a striking complexity of cellular traversal and invasion mechanisms utilized by Apicomplexa parasites for entry into the host cell. For *Plasmodium*, we focus on the two mammalian cell types into which the parasites invade, namely the liver hepatocyte and the erythrocyte. *Toxoplasma* is known to invade all nucleated cells, both non-phagocytic and phagocytic cells. For both species, we discuss notable parasite proteins and organelles involved in each of these invasion processes and highlight the host molecules known to be involved. As these processes represent critical events in the parasite's life cycle, we finish with a brief section describing a number of ongoing efforts to target invasion in an attempt to combat these menacing diseases.

As this is meant to be a general review of Apicomplexan invasion, we regrettably have had to limit the depth of our description. Many excellent reviews exist that are more focused on various aspects of this topic and we direct the reader to these [169–175].

ii. Plasmodium Life Cycle

Five species of *Apicomplexan* parasites of the genus *Plasmodium* infect humans to cause malaria and, like many parasites, they develop through discrete stages, each particularly adapted to one of its two hosts (the human and the female anopheline mosquito). These include *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale* and, shown recently to infect humans, *P. knowlesi* [176]. A striking feature of these parasites is their ability to invade a wide variety of cell types during this complex life cycle. This cycle can be broken down into eight steps: 1) In the midgut of an infected female mosquito, the definitive host, diploid zygotes migrate through the chitinous, cell-free peritrophic matrix and penetrate the midgut epithelium, taking up residence between the epithelium and the midgut basal lamina; 2) The zygotes then develop into oocysts that mature and release motile sporozoites that travel through the mosquito's hemocoel, attaching to and traversing through salivary gland cells to access the interior of the gland; 3) Upon the female mosquito taking a blood meal from the mammalian host, sporozoites are deposited in dermal tissue and use gliding motility to reach dermal vessels, crossing the endothelium into the bloodstream; 4) Sporozoites then rapidly (within minutes) migrate to and cross the sinusoids of the liver by traversal through resident macrophages, called Kupffer cells. Once in the liver parenchyma, sporozoites trans-migrate through a number of hepatocytes by a membrane wounding process, after which they eventually invade a hepatocyte through invagination of the hepatocyte membrane; 5) Within the hepatocyte, sporozoites develop into exoerythrocytic forms that differentiate and replicate to produce haploid merozoites, which are then released into the peripheral bloodstream; 6) Merozoites invade erythrocytes, initiating the erythrocytic cycle of infection. During the erythrocytic stages, parasites replicate and progress through the following developmental stages within erythrocytes: ring, trophozoite and schizont. Merozoites egress from the erythrocyte and re-invade uninfected erythrocytes in a 48–72 hour cycle, dependent on the species; 7) During this cycle of development and re-invasion of erythrocytes, some parasites transform into sexual gametes; 8) Gametocytes are taken up by a mosquito, and fertilize to become zygotes, thus completing the life cycle [176].

iii. Plasmodium invasion of the hepatocyte

Invasion of a liver hepatocyte is perhaps best thought of as an ordered process of both extracellular and intracellular steps with the inhibition of any of these resulting in a block in infection. After traversing the dermal epithelium and entry to the bloodstream, sporozoites are carried to the liver where they arrest and undergo gliding motility on the surface of the sinusoids that form the reticuloendothelial system. This is proposed to be mediated through a multivalent interaction of the parasite's surface-expressed circumsporozoite protein (CSP) and thrombospondin-related adhesive protein (TRAP) with sulfated heparin sulfate proteoglycans (HSPGs), secreted by liver stellate cells, that protrude through the endothelial fenestrae into the sinusoidal lumen. This interaction and arrest in the liver sinusoid explains why circulating sporozoites are virtually undetectable within minutes of infection, discovered by intravenously infecting rats with *P. berghei* sporozoites[177]. Traversal of the liver endothelium in rats does not appear to be through the liver endothelial cells, rather it involves a membrane invagination process (with formation of a parasitophorous vacuole) of the Kupffer cells present in the endothelial lining by *P. berghei* and *P. yoelii*[178]. Functional studies to block the activity of these phagocytic cells, either by heat killing or by specific inhibitors, suggested their involvement in sporozoite traversal, with a smaller percentage of traversal explained by a biologically active process[179]. Stronger evidence is from mouse experiments in which macrophage colony-stimulating factor 1 (CSF-1) was knocked out, leading to greatly reduced numbers of Kupffer cells. These mice were significantly less susceptible to *P. yoelii* infection, indicating the necessary role of Kupffer in access to the liver parenchyma[180]. Once in the parenchyma of the liver, sporozoites traverse a number of hepatocytes in a non-invasive, membrane-wounding manner before finally invading a host hepatocyte through invagination and formation of a parasitophorous vacuole.

iv. Plasmodium invasion of the erythrocyte

The merozoites released into the bloodstream from the liver exoerythrocytic cycle are small (~1 micron) and somewhat pear-shaped. At their apical end is located a specialized structure known as the apical complex in which reside specialized secretory organelles called rhoptries and micronemes that contain proteins necessary for invasion (Fig. 3). The limited tropism of merozoites is due to specific ligand-receptor interactions between the parasites and the erythrocytes. Initial interactions occur through proteins covering the surface of the merozoite, followed by a reorientation and formation of a tight junction between the erythrocyte and the apical end of the parasite. One of the best described proteins important in this initial interaction is the GPI-anchored protein, merozoite surface protein-1 (MSP-1) which has been suggested to interact with two nonglycosylated extracellular regions of Band 3 protein on the surface of the erythrocyte[181]. Orientation of the parasite to its apical end approximating the erythrocyte membrane then occurs followed by tight junction formation through high-affinity interactions between parasite ligands and erythrocyte receptors. Two families of proteins, the erythrocyte-binding-like (EBLs) protein and the reticulocyte-bindinglike (RBLs or *P. falciparum* Rh) proteins, have been well recognized as major parasite ligands responsible for binding and invasion and have been shown to play a cooperative role in invasion, as functional loss of the former leads to the increased

transcription of the latter[182]. Both are localized to apical organelles and are released onto the parasite surface during invasion. EBLs and RBLs both appear to have specific receptors on the surface of erythrocytes, such as EBL-175 binding predominantly to glycophorin A[183]. In *P. falciparum* five EBLs and six RBLs have been described. With the exception of PfRh1, all the PfRhs bind in a sialic acid-independent manner and only PfRh4 has an identified receptor, complement receptor 1. Both families are present throughout *Plasmodium* spp. It is notable that *P. falciparum* appears to use multiple and alternative ligand-receptor interactions and is capable of switching invasion mechanisms between sialic acid dependent and sialic acid independent pathways, demonstrated using neuraminidase and trypsin treatments on erythrocytes[184, 185]. In different regions of India and Gambia, field isolates were tested and it was found that the majority of parasites invade by the EBL-175/glycophorin A pathway[186, 187]. However, in Brazil only a minority of field isolates used this pathway[188]. This is evidence that there is variation of invasion mechanisms in field isolates from different regions of the world.

Another well known binding interaction necessary for invasion occurs between the Duffy antigen and the Duffy Binding Protein (DBP) of *P. vivax*. The Duffy antigen, expressed on human erythrocytes, is the binding receptor for a cysteine rich domain of DBP[189]. Duffy negative (Fy(a-b-)) individuals, most commonly found in Western Africa, are naturally resistant to *P. vivax* infection[190]. The Duffy antigen has also been shown vital for *P. knowlesi* binding *in vitro*[191, 192]. The cysteine rich domain in *P. knowlesi* DBP is found to bind to Duffy antigen but with different specificity than that of *P. vivax*[189].

v. *Toxoplasma gondii* Life cycle

T. gondii invades a wide variety of cell types in a life cycle that can be described in four steps: 1) Tachyzoites are the fast growing form that causing acute infection in humans and other animals. These infect nucleated host cells, replicating into a large number of progeny and egress by lysing the host cell; 2) Under immune pressure from the host, the parasite can differentiate into a slow-growing form, termed bradyzoites. This occurs in longliving tissue types such as muscle or neuronal cells; 3) Ingestion of animal tissue bradyzoites, by cats or humans releases parasites in the intestinal tract. In cats this results in sexual development and subsequent shedding of oocysts into the environment and in humans it can lead to disseminated infection; 4) Shed oocysts from cats develop into haploid sporozoites in the environment. The oral ingestion of these sporozoites leads to differentiation into tachyzoites and acute infection by humans or other mammals[193].

vi *Toxoplasma gondii* invasion of host cells

T. gondii tachyzoites use gliding motility, a mechanism not expanded upon in this review, to facilitate movement and interaction with host cells. Like a *Plasmodium* merozoite, surface antigens aid in the interaction between the tachyzoite and the host cell. One antigen known to have membrane-binding activity is Perforinlike Protein 1 (PLP-1), forming pores in the host cell membrane after binding and as well as playing a role in egress[194]. The parasite then re-orient its position such that the apical end has contact with the host cell. *T. gondii* secretes proteins needed for invasion from micronemes, rhoptries and dense granules. The contents of the micronemes are secreted first during the initial contact with the host cell,

including the full length cellular form of microneme protein 2 (MIC2), which binds specifically to the host cell[195]. MIC2, along with MIC1, MIC4, MIC6 and MIC8, is involved in the interaction between the parasite and the host cell[196, 197]. As the parasite invades the target cell these microneme proteins are proteolytically cleaved from the surface of the parasite. The rhoptries then secrete rhoptry neck proteins (RON). RON2 is inserted into the host cell membrane of the host cell being invaded, while RON4, 5, 8, 9, and 10 form a complex at membrane surface of the membrane[198–201]. Tachyzoites then actively invade similar to *Plasmodium* merozoites, with the formation of the moving junction and a motor complex described below.

vii. Process of Apicomplexan invasion

The process of active invasion is so similar in *Plasmodium* and *T. gondii* that this section summarizes this invasion process used by both species of parasites with differences or unique mechanisms specifically noted.

Following tight junction formation between the parasite and the host cell surface, parasites forcibly enter through invagination of the host cell membrane, eventually forming and residing within parasitophorous vacuoles. The process involves a tight junction “motor” termed a moving junction (MJ) (Fig. 3). This junction can be thought of a “ring of contact” between the invading merozoite and the erythrocyte and is used by the parasite to “pull” itself into the cell. Once the parasite is completely inside the host cell, the MJ disappears as the parasitophorous vacuole resolves. No host proteins have been identified in the MJ although studies suggest host cytoskeleton components are involved[202, 203]. The most widely studied parasite protein involved in MJ formation is the apical membrane antigen-1 (AMA1) which is highly conserved across *Plasmodium* species[204–207] and *T. gondii* [200, 208]. AMA1 is secreted by micronemes and interacts with RON2, RON4 and RON5[198, 209] as well as aldolase, an F-actin binding protein. In *T. gondii*, MIC6 also interacts directly with aldolase[196]. The RON proteins are part of a parasite derived protein complex termed the RON complex, which is secreted into the host cell upon MJ formation. The interaction between AMA1 and the RON complex is essential for parasite invasion[209]. In fact, antibodies to AMA1 can block invasion[210] and a 20-residue AMA1 binding peptide also specifically blocks invasion[211, 212], providing evidence that AMA-1 could be a potential vaccine target. As the MJ progresses around the parasite during invasion many proteins are shed from the surface of the parasite[213–215], including AMA-1[216] and PTRAMP[217], a process required for invasion[214, 218, 219]. Recent work in *Plasmodium* has identified a subtilisin-like serine protease, PfSUB2, as the “shedase” responsible for this indispensable event[220]. In addition to the role of SUB2 as a shedase, a number of intramembrane proteases called rhomboids (ROM) are also implicated[215, 221–223]. In *T. gondii*, ROM4 is implicated in cleaving surface proteins to produce a gradient of adhesins, these including MIC2, AMA1, and MIC3[224].

viii. Therapeutic considerations for malaria

There are many drugs that treat malaria, the most recently developed and effective being multi-drug artemisinin therapies. However, to date all current antimalarials have encountered resistant parasites[225], highlighting the great need for continued drug

development. Theoretically, a drug or vaccine that targets invasion of either hepatocytes or erythrocytes can be a useful preventative measure or treatment for malaria. Recent vaccine strategies are focusing on antigens crucial to invasion of hepatocytes, such as CSP, or of erythrocytes, such as EBLs and RBLs. Due to functional redundancy and antigen switching, multi-antigen vaccine strategies are more likely to act synergistically, reducing the chance of resistance and showing a more effective immune response.

Targeting hepatocytes invasion could be a great tool for prophylaxis drugs, vaccines or treatments to prevent recurrent malaria, as in the case of a *P. vivax* infection. The vaccine RTS,S, which is based on CSP from *P. vivax*, was recently reported in phase 3 clinical trials in Africa to be effective at decreasing the malaria rate in young children by nearly 50% [226, 227]. Serum from rabbits treated with this *P. vivax* CSP based vaccine has shown cross-species recognition of *P. falciparum* and *P. berghei* sporozoites, which is promising for the use of RTS,S against malaria caused by the various species of *Plasmodium* or even mixed infections [228].

Targeting erythrocytic invasion proteins could also serve as a useful vaccine strategy. Studies of polymorphisms of invasion-related ligands PfEBL and PfRh in field isolates from Colombia, Peru and Brazil highlight the importance of understanding the variety of invasion pathways being utilized by parasites in different geographical regions [229]. This needs to be taken into account by developing multi-targeted vaccines, which might overcome “vaccine resistance” and be effective against parasites from different regions, different species of parasites, or mixed infections. As an additional example of this, antibodies against PfRh5 used in combination with seven other merozoite antigens, most notably PfRh4, have been shown to act synergistically in inhibiting growth of *P. falciparum* in culture [230].

Drug-targets include the proteases involved in invasion due to the essentiality of these proteases in egress and re-invasion of erythrocytes. Two peptidyl alpha-ketoamides based on the *P. falciparum* subtilisin-like protease 1 (SUB1) inhibited orthologues in *P. berghei*, *P. vivax* and *P. knowlesi*, suggesting the possibility of “pan-reactive” drugs based on this protease [231]. *P. falciparum* signal peptide peptidase, an intramembrane aspartyl protease associated with micronemes, is shown to interact with a transmembrane receptor on host erythrocytes and antibodies against it block invasion by *P. falciparum* *in vitro* [232]. Rhomboid proteases may also provide an effective drug target as they are essential to invasion [233, 234]. And as mentioned previously, the AMA1 and RON complex interaction is also of interest in vaccine development as antibodies and binding peptides to AMA-1 block invasion [210, 211, 220].

ix. Therapeutic considerations for toxoplasmosis

Toxoplasmosis is also a treatable Apicomplexan disease, although careful consideration is needed for pregnant women and immune-compromised patients like those infected with HIV. Most medications target only the tachyzoite, leaving the bradyzoite unharmed. Current medications include pyrimethamine, which is also a malaria medication, and sulfadiazine. Vaccine studies using these invasion proteins have been relatively successful. A recent study has shown that a ROP8 DNA-based vaccine, encoding one of the rhoptry proteins secreted and essential for invasion, has induced a protective immune response in mice [235]. A DNA

vaccine using a fusion protein of PLP-1 and MIC6 induced protective immunity in mice[236], as did MIC1 and MIC4[237], indicating that these are promising candidates for vaccines. It is likely that other targets of invasion, as mentioned above for malaria, could also make good drug targets for toxoplasmosis.

Overall, invasion and traversal are crucial mechanisms for Apicomplexan parasite survival and infectivity. With multiple invasion events in multiple cell types, the molecular components of invasion are attractive targets for multi-component drugs and/or vaccines, which have the potential to both increase protective immune responses in humans and decrease chance of parasite resistance.

References

1. Kane MM, Mosser DM. Leishmania parasites and their ploys to disrupt macrophage activation. *Curr Opin Hematol.* 2000; 7:26–31. [PubMed: 10608501]
2. Rogers ME, Chance ML, Bates PA. The role of promastigote secretory gel in the origin and transmission of the infective stage of *Leishmania mexicana* by the sandfly *Lutzomyia longipalpis*. *Parasitology.* 2002; 124:495–507. [PubMed: 12049412]
3. Gossage SM, Rogers ME, Bates PA. Two separate growth phases during the development of *Leishmania* in sand flies: implications for understanding the life cycle. *Int J Parasitol.* 2003; 33:1027–1034. [PubMed: 13129524]
4. Kamhawi S. Phlebotomine sand flies and *Leishmania* parasites: friends or foes? *Trends Parasitol.* 2006; 22:439–445. [PubMed: 16843727]
5. Sacks DL, Perkins PV. Development of infective stage *Leishmania* promastigotes within phlebotomine sand flies. *Am J Trop Med Hyg.* 1985; 34:456–459. [PubMed: 4039899]
6. Kimblin N, Peters N, Debrabant A, et al. Quantification of the infectious dose of *Leishmania major* transmitted to the skin by single sand flies. *Proc Natl Acad Sci USA.* 2008; 105:10125–10130. [PubMed: 18626016]
7. le Fichoux YY, Quaranta JFJ, Aufeuvre JPI, et al. Occurrence of *Leishmania infantum* parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. *J Clin Microbiol.* 1999; 37:1953–1957. [PubMed: 10325353]
8. Scarlata F, Vitale F, Saporito L, et al. Asymptomatic *Leishmania infantum*/chagasi infection in blood donors of western Sicily. *Trans R Soc Trop Med Hyg.* 2008; 102:3–3. [PubMed: 17727907]
9. Da Silva RP, Hall BF, Joiner KA, Sacks DL. CR1, the C3b receptor, mediates binding of infective *Leishmania major* metacyclic promastigotes to human macrophages. *J Immunol.* 1989; 143:617–622. [PubMed: 2525590]
10. Mosser DM, Edelson PJ. The third component of complement (C3) is responsible for the intracellular survival of *Leishmania major*. *Nature.* 1987; 327:329–331. [PubMed: 3035377]
11. Puentes SM, Da Silva RP, Sacks DL, et al. Serum resistance of metacyclic stage *Leishmania major* promastigotes is due to release of C5b-9. *J Immunol.* 1990; 145:4311–4316. [PubMed: 2147941]
12. Hermoso T, Fishelson Z, Becker SI, et al. Leishmanial protein kinases phosphorylate components of the complement system. *EMBO J.* 1991; 10:4061–4067. [PubMed: 1756717]
13. Brittingham A, Morrison CJ, McMaster WR, et al. Role of the *Leishmania* surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis. *J Immunol.* 1995; 155:3102–3111. [PubMed: 7673725]
14. Locksley RM, Heinzel FP, Fankhauser JE, et al. Cutaneous host defense in leishmaniasis: interaction of isolated dermal macrophages and epidermal Langerhans cells with the insect-stage promastigote. *Infect Immun.* 1988; 56:336–342. [PubMed: 2828237]
15. Bogdan C, Donhauser N, Döring R, et al. Fibroblasts as host cells in latent leishmaniasis. *J Exp Med.* 2000; 191:2121–2130. [PubMed: 10859337]
16. Titus RG, Ribeiro JM. Salivary gland lysates from the sand fly *Lutzomyia longipalpis* enhance *Leishmania* infectivity. *Science.* 1988; 239:1306–1308. [PubMed: 3344436]

17. Lerner EAE, Ribeiro MJ, Nelson RJ, Lerner MR. Isolation of maxadilan, a potent vasodilatory peptide from the salivary glands of the sand fly *Lutzomyia longipalpis*. *J Biol Chem*. 1991; 266:11234–11236. [PubMed: 2040631]
18. Lerner EA, Shoemaker CB. Maxadilan. Cloning and functional expression of the gene encoding this potent vasodilator peptide. *J Biol Chem*. 1992; 267:1062–1066. [PubMed: 1730635]
19. Anjili CO, Mbatia PA, Mwangi RW, et al. The chemotactic effect of *Phlebotomus duboscqi* (Diptera: Psychodidae) salivary gland lysates to murine monocytes. *Acta Trop*. 1995; 60:97–100. [PubMed: 8610544]
20. Costa DJ, Favali CC, Clarêncio JJ, et al. *Lutzomyia longipalpis* salivary gland homogenate impairs cytokine production and costimulatory molecule expression on human monocytes and dendritic cells. *Infect Immun*. 2004; 72:1298–1305. [PubMed: 14977931]
21. Qureshi AA, Asahina AA, Ohnuma MM, et al. Immunomodulatory properties of maxadilan, the vasodilator peptide from sand fly salivary gland extracts. *Am J Trop Med Hyg*. 1996; 54:665–671. [PubMed: 8686790]
22. Rohousová II, Volf PP, Lipoldová MM. Modulation of murine cellular immune response and cytokine production by salivary gland lysate of three sand fly species. *Parasite Immunol*. 2005; 27:469–473. [PubMed: 16255746]
23. Mbow MLM, Bleyenbergh JAJ, Hall LRL, Titus RGR. *Phlebotomus papatasi* sand fly salivary gland lysate down-regulates a Th1, but up-regulates a Th2, response in mice infected with *Leishmania major*. *J Immunol*. 1998; 161:5571–5577. [PubMed: 9820534]
24. Waitumbi JJ, Warburg AA. *Phlebotomus papatasi* saliva inhibits protein phosphatase activity and nitric oxide production by murine macrophages. *Infect Immun*. 1998; 66:1534–1537. [PubMed: 9529078]
25. Kamhawi S, Belkaid Y, Modi G, et al. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. *Science*. 2000; 290:1351–1354. [PubMed: 11082061]
26. Belkaid YY, Kamhawi SS, Modi GG, et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of *Leishmania major* infection in the mouse ear dermis. *J Exp Med*. 1998; 188:1941–1953. [PubMed: 9815271]
27. Valenzuela JG, Belkaid Y, Garfield MK, et al. Toward a defined anti-*Leishmania* vaccine targeting vector antigens: characterization of a protective salivary protein. *J Exp Med*. 2001; 194:331–342. [PubMed: 11489952]
28. Oliveira F, Lawyer PG, Kamhawi S, Valenzuela JG. Immunity to distinct sand fly salivary proteins primes the anti-*Leishmania* immune response towards protection or exacerbation of disease. *PLoS Negl Trop Dis*. 2008; 2:e226–e226. [PubMed: 18414648]
29. Gomes RR, Teixeira CC, Teixeira MJM, et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. *Proc Natl Acad Sci USA*. 2008; 105:7845–7850. [PubMed: 18509051]
30. Gomes RR, Oliveira FF, Teixeira CC, et al. Immunity to sand fly salivary protein LJM11 modulates host response to vector-transmitted leishmania conferring ulcer-free protection. 2012; 132:2735–2743.
31. Morris RVR, Shoemaker CBC, David JRJ, et al. Sandfly maxadilan exacerbates infection with *Leishmania major* and vaccinating against it protects against *L. major* infection. *J Immunol*. 2001; 167:5226–5230. [PubMed: 11673536]
32. Oliveira FF, Traoré BB, Gomes RR, et al. Delayed-type hypersensitivity to sand fly saliva in humans from a leishmaniasis-endemic area of mali is t(h)1-mediated and persists to midlife. *J Invest Dermatol*. 2013; 133:452–459. [PubMed: 22992802]
33. Ehrchen JM, Roebrock K, Foell D, et al. Keratinocytes determine Th1 immunity during early experimental leishmaniasis. *PLoS Pathog*. 2010; 6:e1000871. [PubMed: 20442861]
34. Ng LG, Hsu A, Mandell MA, et al. Migratory dermal dendritic cells act as rapid sensors of protozoan parasites. *PLoS Pathog*. 2008; 4:e1000222. [PubMed: 19043558]
35. Moll H, Fuchs H, Blank C, Rölinghoff M. Langerhans cells transport *Leishmania major* from the infected skin to the draining lymph node for presentation to antigen-specific T cells. *Eur J Immunol*. 1993; 23:1595–1601. [PubMed: 8325337]

36. Kautz-Neu K, Noordegraaf M, Dinges S, et al. Langerhans cells are negative regulators of the anti-Leishmania response. *J Exp Med*. 2011; 208:885–891. [PubMed: 21536741]
37. Peters NC, Egen JG, Secundino N, et al. In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. *Science*. 2008; 321:970–974. [PubMed: 18703742]
38. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol*. 2007; 81:1–5. [PubMed: 17032697]
39. Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. *Nat Rev Microbiol*. 2011; 9:604–615. [PubMed: 21747391]
40. Pearson RD, Steigbigel RT. Phagocytosis and killing of the protozoan *Leishmania donovani* by human polymorphonuclear leukocytes. *J Immunol*. 1981; 127:1438–1443. [PubMed: 7276565]
41. Chang KP. Leishmanicidal mechanisms of human polymorphonuclear phagocytes. *Am J Trop Med Hyg*. 1981; 30:322–333. [PubMed: 7235125]
42. Guimarães-Costa AB, Nascimento MTC, Froment GS, et al. *Leishmania amazonensis* promastigotes induce and are killed by neutrophil extracellular traps. *Proc Natl Acad Sci USA*. 2009; 106:6748–6753. [PubMed: 19346483]
43. Wenzel UA, Bank E, Florian C, et al. *Leishmania major* parasite stage-dependent host cell invasion and immune evasion. *FASEB J*. 2012; 26:29–39. [PubMed: 21908716]
44. Remaley AT, Kuhns DB, Basford RE, et al. Leishmanial phosphatase blocks neutrophil O-2 production. *J Biol Chem*. 1984; 259:11173–11175. [PubMed: 6088532]
45. Gueirard P, Laplante A, Rondeau C, et al. Trafficking of *Leishmania donovani* promastigotes in non-lytic compartments in neutrophils enables the subsequent transfer of parasites to macrophages. *Cell Microbiol*. 2008; 10:100–111. [PubMed: 17651446]
46. Tuwairi, al AS.; Mofleh, al IA.; Mahmoud, AA. Effect of *Leishmania major* on human polymorphonuclear leucocyte function in vitro. *J Med Microbiol*. 1990; 32:189–193. [PubMed: 2374156]
47. van Zandbergen GG, Hermann NN, Laufs HH, et al. *Leishmania* promastigotes release a granulocyte chemotactic factor and induce interleukin-8 release but inhibit gamma interferon-inducible protein 10 production by neutrophil granulocytes. *Infect Immun*. 2002; 70:4177–4184. [PubMed: 12117926]
48. Wenzel A, van Zandbergen G. Lipoxin A4 receptor dependent leishmania infection. *Autoimmunity*. 2009; 42:331–333. [PubMed: 19811292]
49. Faria MS, Reis FCG, Azevedo-Pereira RL, et al. *Leishmania* inhibitor of serine peptidase 2 prevents TLR4 activation by neutrophil elastase promoting parasite survival in murine macrophages. *J Immunol*. 2011; 186:411–422. [PubMed: 21098233]
50. Aga E, Katschinski DM, van Zandbergen G, et al. Inhibition of the spontaneous apoptosis of neutrophil granulocytes by the intracellular parasite *Leishmania major*. *J Immunol*. 2002; 169:898–905. [PubMed: 12097394]
51. van Zandbergen G, Klinger M, Mueller A, et al. Cutting edge: neutrophil granulocyte serves as a vector for *Leishmania* entry into macrophages. *J Immunol*. 2004; 173:6521–6525. [PubMed: 15557140]
52. Charmoy M, Brunner-Agten S, Aebischer D, et al. Neutrophil-derived CCL3 is essential for the rapid recruitment of dendritic cells to the site of *Leishmania major* inoculation in resistant mice. *PLoS Pathog*. 2010; 6:e1000755. [PubMed: 20140197]
53. Ribeiro-Gomes FL, Peters NC, Debrabant A, Sacks DL. Efficient capture of infected neutrophils by dendritic cells in the skin inhibits the early anti-leishmania response. *PLoS Pathog*. 2012; 8:e1002536. [PubMed: 22359507]
54. Blackwell JM, Ezekowitz RA, Roberts MB, et al. Macrophage complement and lectin-like receptors bind *Leishmania* in the absence of serum. *J Exp Med*. 1985; 162:324–331. [PubMed: 3891904]
55. Brittingham A, Chen G, McGwire BS, et al. Interaction of *Leishmania* gp63 with cellular receptors for fibronectin. *Infect Immun*. 1999; 67:4477–4484. [PubMed: 10456889]
56. Soteriadou KP, Remoundos MS, Katsikas MC, et al. The Ser-Arg-Tyr-Asp region of the major surface glycoprotein of *Leishmania* mimics the Arg-Gly-Asp-Ser cell attachment region of fibronectin. *J Biol Chem*. 1992; 267:13980–13985. [PubMed: 1629196]

57. Ueno N, Wilson ME. Receptor-mediated phagocytosis of *Leishmania*: implications for intracellular survival. *Trends Parasitol.* 2012; 28:335–344. [PubMed: 22726697]
58. Chakraborty P, Ghosh D, Basu MK. Modulation of macrophage mannose receptor affects the uptake of virulent and avirulent *Leishmania donovani* promastigotes. *J Parasitol.* 2001; 87:1023–1027. [PubMed: 11695359]
59. Russell DG, Wright SD. Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of *Leishmania* promastigotes. *J Exp Med.* 1988; 168:279–292. [PubMed: 3294332]
60. Vinet AF, Fukuda M, Turco SJ, Descoteaux A. The *Leishmania donovani* lipophosphoglycan excludes the vesicular proton-ATPase from phagosomes by impairing the recruitment of synaptotagmin V. *PLoS Pathog.* 2009; 5:e1000628. [PubMed: 19834555]
61. Olivier M, Gregory DJ, Forget G. Subversion mechanisms by which *Leishmania* parasites can escape the host immune response: a signaling point of view. *Clin Microbiol Rev.* 2005; 18:293–305. [PubMed: 15831826]
62. Scianimanico S, Desrosiers M, Dermine JF, et al. Impaired recruitment of the small GTPase rab7 correlates with the inhibition of phagosome maturation by *Leishmania donovani* promastigotes. *Cell Microbiol.* 1999; 1:19–32. [PubMed: 11207538]
63. Holm A, Tejle K, Magnusson KE, et al. *Leishmania donovani* lipophosphoglycan causes periphagosomal actin accumulation: correlation with impaired translocation of PKC α and defective phagosome maturation. *Cell Microbiol.* 2001; 3:439–447. [PubMed: 11437830]
64. Lodge R, Descoteaux A. *Leishmania donovani* promastigotes induce periphagosomal F-actin accumulation through retention of the GTPase Cdc42. *Cell Microbiol.* 2005; 7:1647–1658. [PubMed: 16207251]
65. Lodge R, Diallo TO, Descoteaux A. *Leishmania donovani* lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane. *Cell Microbiol.* 2006; 8:1922–1931. [PubMed: 16848789]
66. Antoine JC, Prina E, Jouanne C, Bongrand P. Parasitophorous vacuoles of *Leishmania amazonensis*-infected macrophages maintain an acidic pH. *Infect Immun.* 1990; 58:779–787. [PubMed: 1689700]
67. Antoine JC, Prina E, Lang T, Courret N. The biogenesis and properties of the parasitophorous vacuoles that harbour *Leishmania* in murine macrophages. *Trends Microbiol.* 1998; 6:392–401. [PubMed: 9807783]
68. Lodge R, Descoteaux A. Phagocytosis of *Leishmania donovani* amastigotes is Rac1 dependent and occurs in the absence of NADPH oxidase activation. *Eur J Immunol.* 2006; 36:2735–2744. [PubMed: 16955522]
69. Olivier M, Brownsey RW, Reiner NE. Defective stimulus-response coupling in human monocytes infected with *Leishmania donovani* is associated with altered activation and translocation of protein kinase C. *Proc Natl Acad Sci USA.* 1992; 89:7481–7485. [PubMed: 1323839]
70. Bhattacharyya S, Ghosh S, Jhonson PL, et al. Immunomodulatory role of interleukin-10 in visceral leishmaniasis: defective activation of protein kinase C-mediated signal transduction events. *Infect Immun.* 2001; 69:1499–1507. [PubMed: 11179319]
71. Nandan D, Reiner NE. Attenuation of gamma interferon-induced tyrosine phosphorylation in mononuclear phagocytes infected with *Leishmania donovani*: selective inhibition of signaling through Janus kinases and Stat1. *Infect Immun.* 1995; 63:4495–4500. [PubMed: 7591091]
72. Sen S, Roy K, Mukherjee S, et al. Restoration of IFN γ R subunit assembly, IFN γ signaling and parasite clearance in *Leishmania donovani* infected macrophages: role of membrane cholesterol. *PLoS Pathog.* 2011; 7:e1002229. [PubMed: 21931549]
73. Ghosh S, Bhattacharyya S, Das S, et al. Generation of ceramide in murine macrophages infected with *Leishmania donovani* alters macrophage signaling events and aids intracellular parasitic survival. *Mol Cell Biochem.* 2001; 223:47–60. [PubMed: 11681721]
74. Nandan D, Lo R, Reiner NE. Activation of phosphotyrosine phosphatase activity attenuates mitogen-activated protein kinase signaling and inhibits c-FOS and nitric oxide synthase expression in macrophages infected with *Leishmania donovani*. *Infect Immun.* 1999; 67:4055–4063. [PubMed: 10417174]

75. Ghosh S, Bhattacharyya S, Sirkar M, et al. Leishmania donovani suppresses activated protein 1 and NF-kappaB activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase. *Infect Immun*. 2002; 70:6828–6838. [PubMed: 12438359]
76. Cameron P, McGachy A, Anderson M, et al. Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-kappaB signaling pathway. *J Immunol*. 2004; 173:3297–3304. [PubMed: 15322192]
77. Yang Z, Mosser DM, Zhang X. Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages. *J Immunol*. 2007; 178:1077–1085. [PubMed: 17202371]
78. Mathur RK, Awasthi A, Wadhwa P, et al. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. *Nat Med*. 2004; 10:540–544. [PubMed: 15107845]
79. Srivastava N, Sudan R, Saha B. CD40-modulated dual-specificity phosphatases MAPK phosphatase (MKP)-1 and MKP-3 reciprocally regulate Leishmania major infection. *J Immunol*. 2011; 186:5863–5872. [PubMed: 21471446]
80. Jaramillo M, Gomez MA, Larsson O, et al. Leishmania repression of host translation through mTOR cleavage is required for parasite survival and infection. *Cell Host Microbe*. 2011; 9:331–341. [PubMed: 21501832]
81. Wilson J, Huynh C, Kennedy KA, et al. Control of parasitophorous vacuole expansion by LYST/Beige restricts the intracellular growth of Leishmania amazonensis. *PLoS Pathog*. 2008; 4:e1000179. [PubMed: 18927622]
82. Cummings HE, Barbi J, Reville P, et al. Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. *Proc Natl Acad Sci USA*. 2012; 109:1251–1256. [PubMed: 22232690]
83. Kar S, Ukil A, Das PK. Cystatin cures visceral leishmaniasis by NF-κB-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-Tp12-ERK pathway. *Eur J Immunol*. 2011; 41:116–127. [PubMed: 21182083]
84. Das L, Datta N, Bandyopadhyay S, Das PK. Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response. *J Immunol*. 2001; 166:4020–4028. [PubMed: 11238649]
85. Banerjee S, Ghosh J, Sen S, et al. Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. *Infect Immun*. 2009; 77:2330–2342. [PubMed: 19289510]
86. Ghosh J, Das S, Guha R, et al. Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol. *J Lipid Res*. 2012; 53:2560–2572. [PubMed: 23060454]
87. Vilhardt F, van Deurs B. The phagocyte NADPH oxidase depends on cholesterol-enriched membrane microdomains for assembly. *EMBO J*. 2004; 23:739–748. [PubMed: 14765128]
88. Chakraborty D, Banerjee S, Sen A, et al. Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. *J Immunol*. 2005; 175:3214–3224. [PubMed: 16116212]
89. Delaporte, F. Chagas Disease: History of a Continent's Scourge. Fordham University Press; 2012.
90. Van Overtvelt L, Vanderheyde N, Verhasselt V, et al. Trypanosoma cruzi infects human dendritic cells and prevents their maturation: inhibition of cytokines, HLA-DR, and costimulatory molecules. *Infect Immun*. 1999; 67:4033–4040. [PubMed: 10417171]
91. Coura JR. [Transmission of chagasic infection by oral route in the natural history of Chagas disease]. *Rev Soc Bras Med Trop*. 2006; 39(Suppl 3):113–117. [PubMed: 17605219]
92. Pinto AYDN, Valente SA, Valente VDC, et al. [Acute phase of Chagas disease in the Brazilian Amazon region: study of 233 cases from Pará, Amapá and Maranhão observed between 1988 and 2005]. *Rev Soc Bras Med Trop*. 2008; 41:602–614. [PubMed: 19142440]
93. Marcili A, Valente VC, Valente SA, et al. Trypanosoma cruzi in Brazilian Amazonia: Lineages TCI and TCIIa in wild primates, Rhodnius spp. and in humans with Chagas disease associated with oral transmission. *Int J Parasitol*. 2009; 39:615–623. [PubMed: 19041313]
94. Nóbrega AA, Garcia MH, Tatto E, et al. Oral transmission of Chagas disease by consumption of açai palm fruit, Brazil. *Emerging Infect Dis*. 2009; 15:653–655. [PubMed: 19331764]

95. Alarcón de Noya B, Díaz-Bello Z, Colmenares C, et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. *J Infect Dis.* 2010; 201:1308–1315. [PubMed: 20307205]
96. Fitzpatrick MA, Caicedo JC, Stosor V, Ison MG. Expanded infectious diseases screening program for Hispanic transplant candidates. *Transpl Infect Dis.* 2010; 12:336–341. [PubMed: 20534036]
97. Bern CC, Montgomery SPS, Katz LL, et al. Chagas disease and the US blood supply. *Curr Opin Infect Dis.* 2008; 21:476–482. [PubMed: 18725796]
98. Maeda FY, Cortez C, Yoshida N. Cell signaling during *Trypanosoma cruzi* invasion. *Front Immunol.* 2012; 3:361. [PubMed: 23230440]
99. Nagajyothi F, Machado FS, Burleigh BA, et al. Mechanisms of *Trypanosoma cruzi* persistence in Chagas disease. *Cell Microbiol.* 2012; 14:634–643. [PubMed: 22309180]
100. Fernandes MC, Andrews NW. Host cell invasion by *Trypanosoma cruzi*: a unique strategy that promotes persistence. *FEMS Microbiol Rev.* 2012; 36:734–747. [PubMed: 22339763]
101. Burleigh BA, Woolsey AM. Cell signalling and *Trypanosoma cruzi* invasion. *Cell Microbiol.* 2002; 4:701–711. [PubMed: 12427093]
102. Weston D, Patel B, Van Voorhis WC. Virulence in *Trypanosoma cruzi* infection correlates with the expression of a distinct family of sialidase superfamily genes. *Mol Biochem Parasitol.* 1999; 98:105–116. [PubMed: 10029313]
103. Egima CM, Briones MR, Freitas Júnior LH, et al. Organization of trans-sialidase genes in *Trypanosoma cruzi*. *Mol Biochem Parasitol.* 1996; 77:115–125. [PubMed: 8813658]
104. Manque PM, Eichinger D, Juliano MA, et al. Characterization of the cell adhesion site of *Trypanosoma cruzi* metacyclic stage surface glycoprotein gp82. *Infect Immun.* 2000; 68:478–484. [PubMed: 10639407]
105. Ramirez MI, Boscardin SB, Han SW, et al. Heterologous expression of a *Trypanosoma cruzi* surface glycoprotein (gp82) in mammalian cells indicates the existence of different signal sequence requirements and processing. *J Eukaryot Microbiol.* 1999; 46:557–565. [PubMed: 10568029]
106. Cortez M, Neira I, Ferreira D, et al. Infection by *Trypanosoma cruzi* metacyclic forms deficient in gp82 but expressing a related surface molecule, gp30. *Infect Immun.* 2003; 71:6184–6191. [PubMed: 14573635]
107. Ruiz RC, Favoreto S, Dorta ML, et al. Infectivity of *Trypanosoma cruzi* strains is associated with differential expression of surface glycoproteins with differential Ca²⁺ signalling activity. *Biochem J.* 1998; 330(Pt 1):505–511. [PubMed: 9461549]
108. Málaga S, Yoshida N. Targeted reduction in expression of *Trypanosoma cruzi* surface glycoprotein gp90 increases parasite infectivity. *Infect Immun.* 2001; 69:353–359. [PubMed: 11119524]
109. Yoshida N, Cortez M. *Trypanosoma cruzi*: parasite and host cell signaling during the invasion process. *Subcell Biochem.* 2008; 47:82–91. [PubMed: 18512343]
110. Andrade D, Serra R, Svensjö E, et al. *Trypanosoma cruzi* invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy. *Br J Pharmacol.* 2012; 165:1333–1347. [PubMed: 21797847]
111. Scharfstein J, Schmitz V, Morandi V, et al. Host cell invasion by *Trypanosoma cruzi* is potentiated by activation of bradykinin B(2) receptors. *J Exp Med.* 2000; 192:1289–1300. [PubMed: 11067878]
112. Caler EV, Morty RE, Burleigh BA, Andrews NW. Dual role of signaling pathways leading to Ca(2+) and cyclic AMP elevation in host cell invasion by *Trypanosoma cruzi*. *Infect Immun.* 2000; 68:6602–6610. [PubMed: 11083771]
113. Caler EV, Vaena de Avalos S, Haynes PA, et al. Oligopeptidase B-dependent signaling mediates host cell invasion by *Trypanosoma cruzi*. *EMBO J.* 1998; 17:4975–4986. [PubMed: 9724634]
114. Burleigh BA, Caler EV, Webster P, Andrews NW. A cytosolic serine endopeptidase from *Trypanosoma cruzi* is required for the generation of Ca²⁺ signaling in mammalian cells. *J Cell Biol.* 1997; 136:609–620. [PubMed: 9024691]

115. Schenkman S, Kurosaki T, Ravetch JV, Nussenzweig V. Evidence for the participation of the Ssp-3 antigen in the invasion of nonphagocytic mammalian cells by *Trypanosoma cruzi*. *J Exp Med*. 1992; 175:1635–1641. [PubMed: 1534115]
116. Schenkman S, Jiang MS, Hart GW, Nussenzweig V. A novel cell surface transsialidase of *Trypanosoma cruzi* generates a stage-specific epitope required for invasion of mammalian cells. *Cell*. 1991; 65:1117–1125. [PubMed: 1712251]
117. Andrews NW, Hong KS, Robbins ES, Nussenzweig V. Stage-specific surface antigens expressed during the morphogenesis of vertebrate forms of *Trypanosoma cruzi*. *Exp Parasitol*. 1987; 64:474–484. [PubMed: 3315736]
118. Chuenkova MV, PereiraPerrin M. *Trypanosoma cruzi* targets Akt in host cells as an intracellular antiapoptotic strategy. *Sci Signal*. 2009; 2:ra74. [PubMed: 19920252]
119. Chuenkova MV, PereiraPerrin M. Chagas' disease parasite promotes neuron survival and differentiation through TrkA nerve growth factor receptor. *J Neurochem*. 2004; 91:385–394. [PubMed: 15447671]
120. Chuenkova MV, Furnari FB, Cavenee WK, Pereira MA. *Trypanosoma cruzi* transsialidase: a potent and specific survival factor for human Schwann cells by means of phosphatidylinositol 3-kinase/Akt signaling. *Proc Natl Acad Sci USA*. 2001; 98:9936–9941. [PubMed: 11481434]
121. Santana JM, Grellier P, Schrével J, Teixeira AR. A *Trypanosoma cruzi*-secreted 80 kDa proteinase with specificity for human collagen types I and IV. *Biochem J*. 1997; 325(Pt 1):129–137. [PubMed: 9224638]
122. Moody TN, Ochieng J, Villalta F. Novel mechanism that *Trypanosoma cruzi* uses to adhere to the extracellular matrix mediated by human galectin-3. *FEBS Lett*. 2000; 470:305–308. [PubMed: 10745086]
123. Alves MJM, Colli W. Role of the gp85/trans-sialidase superfamily of glycoproteins in the interaction of *Trypanosoma cruzi* with host structures. *Subcell Biochem*. 2008; 47:58–69. [PubMed: 18512341]
124. Nde PN, Lima MF, Johnson CA, et al. Regulation and use of the extracellular matrix by *Trypanosoma cruzi* during early infection. *Front Immunol*. 2012; 3:337. [PubMed: 23133440]
125. Ortega-Barria E, Pereira ME. Entry of *Trypanosoma cruzi* into eukaryotic cells. *Infect Agents Dis*. 1992; 1:136–145. [PubMed: 1365537]
126. Ortega-Barria E, Pereira ME. A novel T. cruzi heparin-binding protein promotes fibroblast adhesion and penetration of engineered bacteria and trypanosomes into mammalian cells. *Cell*. 1991; 67:411–421. [PubMed: 1655283]
127. Kulkarni MM, Olson CL, Engman DM, McGwire BS. *Trypanosoma cruzi* GP63 proteins undergo stage-specific differential posttranslational modification and are important for host cell infection. *Infect Immun*. 2009; 77:2193–2200. [PubMed: 19273559]
128. Cuevas IC, Cazzulo JJ, Sánchez DO. gp63 homologues in *Trypanosoma cruzi*: surface antigens with metalloprotease activity and a possible role in host cell infection. *Infect Immun*. 2003; 71:5739–5749. [PubMed: 14500495]
129. Andrade LO, Andrews NW. The *Trypanosoma cruzi*-host-cell interplay: location, invasion, retention. *Nat Rev Microbiol*. 2005; 3:819–823. [PubMed: 16175174]
130. Fernandes MC, Cortez M, Flannery AR, et al. *Trypanosoma cruzi* subverts the sphingomyelinase-mediated plasma membrane repair pathway for cell invasion. *J Exp Med*. 2011; 208:909–921. [PubMed: 21536739]
131. Chakrabarti S, Andrade LO, Andrews NW. *Trypanosoma cruzi* invades synaptotagmin VII-deficient cells by a PI-3 kinase independent pathway. *Mol Biochem Parasitol*. 2005; 141:125–128. [PubMed: 15811535]
132. Caler EV, Chakrabarti S, Fowler KT, et al. The Exocytosis-regulatory protein synaptotagmin VII mediates cell invasion by *Trypanosoma cruzi*. *J Exp Med*. 2001; 193:1097–1104. [PubMed: 11342594]
133. Woolsey AM, Burleigh BA. Host cell actin polymerization is required for cellular retention of *Trypanosoma cruzi* and early association with endosomal/lysosomal compartments. *Cell Microbiol*. 2004; 6:829–838. [PubMed: 15272864]

134. Woolsey AM, Sunwoo L, Petersen CA, et al. Novel PI 3-kinase-dependent mechanisms of trypanosome invasion and vacuole maturation. *J Cell Sci.* 2003; 116:3611–3622. [PubMed: 12876217]
135. Barrias ES, Reignault LC, De Souza W, Carvalho TMU. Dynasore, a dynamin inhibitor, inhibits *Trypanosoma cruzi* entry into peritoneal macrophages. *PLoS ONE.* 2010; 5:e7764. [PubMed: 20098746]
136. Wilkowsky SE, Barbieri MA, Stahl PD, Isola ELD. Regulation of *Trypanosoma cruzi* invasion of nonphagocytic cells by the endocytically active GTPases dynamin, Rab5, and Rab7. *Biochem Biophys Res Commun.* 2002; 291:516–521. [PubMed: 11855818]
137. Andrade LO, Andrews NW. Lysosomal fusion is essential for the retention of *Trypanosoma cruzi* inside host cells. *J Exp Med.* 2004; 200:1135–1143. [PubMed: 15520245]
138. Romano PS, Arboit MA, Vázquez CL, Colombo MI. The autophagic pathway is a key component in the lysosomal dependent entry of *Trypanosoma cruzi* into the host cell. *Autophagy.* 2009; 5:6–18. [PubMed: 19115481]
139. Alvarez VE, Kosec G, Sant Anna C, et al. Blocking autophagy to prevent parasite differentiation: a possible new strategy for fighting parasitic infections? *Autophagy.* 2008; 4:361–363. [PubMed: 18212533]
140. Alvarez VE, Kosec G, Sant'Anna C, et al. Autophagy is involved in nutritional stress response and differentiation in *Trypanosoma cruzi*. *J Biol Chem.* 2008; 283:3454–3464. [PubMed: 18039653]
141. Barclay JJ, Morosi LG, Vanrell MC, et al. *Trypanosoma cruzi* Coexpressing Ornithine Decarboxylase and Green Fluorescence Proteins as a Tool to Study the Role of Polyamines in Chagas Disease Pathology. *Enzyme Res.* 2011; 2011:657460. [PubMed: 21687606]
142. Mortara RA, Andreoli WK, Fernandes MCDC, et al. Host cell actin remodeling in response to *Trypanosoma cruzi*: trypomastigote versus amastigote entry. *Subcell Biochem.* 2008; 47:101–109. [PubMed: 18512345]
143. Mortara RA, Andreoli WK, Taniwaki NN, et al. Mammalian cell invasion and intracellular trafficking by *Trypanosoma cruzi* infective forms. *An Acad Bras Cienc.* 2005; 77:77–94. [PubMed: 15692679]
144. Fernandes MC, Flannery AR, Andrews N, Mortara RA. Extracellular amastigotes of *Trypanosoma cruzi* are potent inducers of phagocytosis in mammalian cells. *Cell Microbiol.* 2012
145. Yoshida N. *Trypanosoma cruzi* infection by oral route: how the interplay between parasite and host components modulates infectivity. *Parasitol Int.* 2008; 57:105–109. [PubMed: 18234547]
146. Neira I, Silva FA, Cortez M, Yoshida N. Involvement of *Trypanosoma cruzi* metacyclic trypomastigote surface molecule gp82 in adhesion to gastric mucin and invasion of epithelial cells. *Infect Immun.* 2003; 71:557–561. [PubMed: 12496211]
147. Yoshida N. Molecular mechanisms of *Trypanosoma cruzi* infection by oral route. *Mem Inst Oswaldo Cruz.* 2009; 104(Suppl 1):101–107. [PubMed: 19753464]
148. Covarrubias C, Cortez M, Ferreira D, Yoshida N. Interaction with host factors exacerbates *Trypanosoma cruzi* cell invasion capacity upon oral infection. *Int J Parasitol.* 2007; 37:1609–1616. [PubMed: 17640647]
149. Alvarez MN, Peluffo G, Piacenza L, Radi R. Intraphagosomal peroxynitrite as a macrophage-derived cytotoxin against internalized *Trypanosoma cruzi*: consequences for oxidative killing and role of microbial peroxiredoxins in infectivity. *J Biol Chem.* 2011; 286:6627–6640. [PubMed: 21098483]
150. Thomson L, Gadelha FR, Peluffo G, et al. Peroxynitrite affects Ca²⁺ transport in *Trypanosoma cruzi*. *Mol Biochem Parasitol.* 1999; 98:81–91. [PubMed: 10029311]
151. Rubbo H, Denicola A, Radi R. Peroxynitrite inactivates thiol-containing enzymes of *Trypanosoma cruzi* energetic metabolism and inhibits cell respiration. *Arch Biochem Biophys.* 1994; 308:96–102. [PubMed: 8311481]
152. Hissa B, Duarte JG, Kelles LF, et al. Membrane cholesterol regulates lysosomeplasma membrane fusion events and modulates *Trypanosoma cruzi* invasion of host cells. *PLoS Negl Trop Dis.* 2012; 6:e1583. [PubMed: 22479662]

153. Barrias ES, Dutra JMF, de Souza W, Carvalho TMU. Participation of macrophage membrane rafts in *Trypanosoma cruzi* invasion process. *Biochem Biophys Res Commun*. 2007; 363:828–834. [PubMed: 17904520]
154. Fernandes MC, Cortez M, Geraldo Yoneyama KA, et al. Novel strategy in *Trypanosoma cruzi* cell invasion: implication of cholesterol and host cell microdomains. *Int J Parasitol*. 2007; 37:1431–1441. [PubMed: 17582418]
155. Kedderis GL, Miwa GT. The metabolic activation of nitroheterocyclic therapeutic agents. *Drug Metab Rev*. 1988; 19:33–62. [PubMed: 3293954]
156. Viodé C, Bettache N, Cenas N, et al. Enzymatic reduction studies of nitroheterocycles. *Biochem Pharmacol*. 1999; 57:549–557. [PubMed: 9952319]
157. Maya JD, Bollo S, Nuñez-Vergara LJ, et al. *Trypanosoma cruzi*: effect and mode of action of nitroimidazole and nitrofuran derivatives. *Biochem Pharmacol*. 2003; 65:999–1006. [PubMed: 12623132]
158. Docampo R, Moreno SN. Free radical metabolism of antiparasitic agents. *Fed Proc*. 1986; 45:2471–2476. [PubMed: 3017765]
159. Gonzalez NS, Cazzulo JJ. Effects of trypanocidal drugs on protein biosynthesis in vitro and in vivo by *Trypanosoma cruzi*. *Biochem Pharmacol*. 1989; 38:2873–2877. [PubMed: 2673249]
160. Matta Guedes PM, Gutierrez FRS, Nascimento MSL, et al. Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: current evidence. *Trop Med Int Health*. 2012; 17:1057–1065. [PubMed: 22686518]
161. Marin-Neto JA, Rassi A, Avezum A, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. *Mem Inst Oswaldo Cruz*. 2009; 104(Suppl 1):319–324. [PubMed: 19753491]
162. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early *Trypanosoma cruzi* infection. *Lancet*. 1996; 348:1407–1413. [PubMed: 8937280]
163. Sajid M, Robertson SA, Brinen LS, McKerrow JH. Cruzain : the path from target validation to the clinic. *Adv Exp Med Biol*. 2011; 712:100–115. [PubMed: 21660661]
164. Doyle PS, Zhou YM, Engel JC, McKerrow JH. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. *Antimicrob Agents Chemother*. 2007; 51:3932–3939. [PubMed: 17698625]
165. Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by *Trypanosoma cruzi*. *Antimicrob Agents Chemother*. 2005; 49:5160–5161. [PubMed: 16304193]
166. Jose Cazzulo J, Stoka V, Turk V. The major cysteine proteinase of *Trypanosoma cruzi*: a valid target for chemotherapy of Chagas disease. *Curr Pharm Des*. 2001; 7:1143–1156. [PubMed: 11472258]
167. World Health Organization (WHO). Guidelines for the treatment of malaria. Geneva, Switzerland: WHO; 2010. p. 1942010
168. Centers for Disease Control and Prevention (CDC). Parasites – Toxoplasmosis. Georgia, U.S.A: CDC; 2013. 2013. <http://www.cdc.gov/toxoplasmosis/>
169. Baum J, Gilberger T-W, Frischknecht F, Meissner M. Host-cell invasion by malaria parasites: insights from *Plasmodium* and *Toxoplasma*. *Trends Parasitol*. 2008; 24:557–563. [PubMed: 18835222]
170. Ménard R. The journey of the malaria sporozoite through its hosts: two parasite proteins lead the way. *Microbes Infect*. 2000; 2:633–642. [PubMed: 10884614]
171. Ghosh A, Edwards MJ, Jacobs-Lorena M. The journey of the malaria parasite in the mosquito: hopes for the new century. *Parasitol Today (Regul Ed)*. 2000; 16:196–201. [PubMed: 10782078]
172. Tyler JS, Treeck M, Boothroyd JC. Focus on the ringleader: the role of AMA1 in apicomplexan invasion and replication. *Trends Parasitol*. 2011; 27:410–420. [PubMed: 21659001]
173. Kappe SHI, Kaiser K, Matuschewski K. The *Plasmodium* sporozoite journey: a rite of passage. *Trends Parasitol*. 2003; 19:135–143. [PubMed: 12643997]
174. Shen B, Sibley LD. The moving junction, a key portal to host cell invasion by apicomplexan parasites. *Curr Opin Microbiol*. 2012; 15:449–455. [PubMed: 22445360]

175. Sibley LD. Invasion and intracellular survival by protozoan parasites. *Immunol Rev.* 2011; 240:72–91. [PubMed: 21349087]
176. Garcia CR, de Azevedo MF, Wunderlich G, et al. Plasmodium in the postgenomic era: new insights into the molecular cell biology of malaria parasites. *Int Rev Cell Mol Biol.* 2008; 266:85–156. [PubMed: 18544493]
177. Shin SC, Vanderberg JP, Terzakis JA. Direct infection of hepatocytes by sporozoites of *Plasmodium berghei*. *J Protozool.* 1982; 29:448–454. [PubMed: 6752394]
178. Pradel G, Frevert U. Malaria sporozoites actively enter and pass through rat Kupffer cells prior to hepatocyte invasion. *Hepatology.* 2001; 33:1154–1165. [PubMed: 11343244]
179. Sihden RE, Smith JE. The role of the Kupffer cell in the infection of rodents by sporozoites of *Plasmodium*: uptake of sporozoites by perfused liver and the establishment of infection in vivo. *Acta Trop.* 1982; 39:11–27. [PubMed: 6122359]
180. Baer K, Roosevelt M, Clarkson AB, et al. Kupffer cells are obligatory for *Plasmodium yoelii* sporozoite infection of the liver. *Cell Microbiol.* 2007; 9:397–412. [PubMed: 16953803]
181. Goel VK, Li X, Chen H, et al. Band 3 is a host receptor binding merozoite surface protein 1 during the *Plasmodium falciparum* invasion of erythrocytes. *Proc Natl Acad Sci USA.* 2003; 100:5164–5169. [PubMed: 12692305]
182. Lopatnicki S, Maier AG, Thompson J, et al. Reticulocyte and erythrocyte binding-like proteins function cooperatively in invasion of human erythrocytes by malaria parasites. *Infect Immun.* 2011; 79:1107–1117. [PubMed: 21149582]
183. Dolan SA, Proctor JL, Alling DW, et al. Glycophorin B as an EBA-175 independent *Plasmodium falciparum* receptor of human erythrocytes. *Mol Biochem Parasitol.* 1994; 64:55–63. [PubMed: 8078523]
184. Dolan SA, Miller LH, Wellems TE. Evidence for a switching mechanism in the invasion of erythrocytes by *Plasmodium falciparum*. *J Clin Invest.* 1990; 86:618–624. [PubMed: 2200806]
185. Mitchell GH, Hadley TJ, McGinniss MH, et al. Invasion of erythrocytes by *Plasmodium falciparum* malaria parasites: evidence for receptor heterogeneity and two receptors. *Blood.* 1986; 67:1519–1521. [PubMed: 3516259]
186. Okoyeh JN, Pillai CR, Chitnis CE. *Plasmodium falciparum* field isolates commonly use erythrocyte invasion pathways that are independent of sialic acid residues of glycophorin A. *Infect Immun.* 1999; 67:5784–5791. [PubMed: 10531229]
187. Baum J, Pinder M, Conway DJ. Erythrocyte invasion phenotypes of *Plasmodium falciparum* in The Gambia. *Infect Immun.* 2003; 71:1856–1863. [PubMed: 12654801]
188. Lobo C-A, de Frazao K, Rodriguez M, et al. Invasion profiles of Brazilian field isolates of *Plasmodium falciparum*: phenotypic and genotypic analyses. *Infect Immun.* 2004; 72:5886–5891. [PubMed: 15385490]
189. Chitnis CE, Miller LH. Identification of the erythrocyte binding domains of *Plasmodium vivax* and *Plasmodium knowlesi* proteins involved in erythrocyte invasion. *J Exp Med.* 1994; 180:497–506. [PubMed: 8046329]
190. Gelpi AP, King MC. Association of Duffy blood groups with the sickle cell trait. *Hum Genet.* 1976; 32:65–68. [PubMed: 1262023]
191. Mason SJ, Miller LH, Shiroishi T, et al. The Duffy blood group determinants: their role in the susceptibility of human and animal erythrocytes to *Plasmodium knowlesi* malaria. *Br J Haematol.* 1977; 36:327–335. [PubMed: 70210]
192. Miller LH, Mason SJ, Dvorak JA, et al. Erythrocyte receptors for (*Plasmodium knowlesi*) malaria: Duffy blood group determinants. *Science.* 1975; 189:561–563. [PubMed: 1145213]
193. Dubey JP, Lindsay DS, Speer CA. Structures of *Toxoplasma gondii* tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. *Clin Microbiol Rev.* 1998; 11:267–299. [PubMed: 9564564]
194. Roiko MS, Carruthers VB. Functional Dissection of *Toxoplasma gondii* Perforin-like Protein 1 Reveals a Dual Domain Mode of Membrane Binding for Cytolysis and Parasite Egress. *J Biol Chem.* 2013; 288:8712–8725. [PubMed: 23376275]
195. Carruthers VB, Giddings OK, Sibley LD. Secretion of micronemal proteins is associated with *Toxoplasma* invasion of host cells. *Cell Microbiol.* 1999; 1:225–235. [PubMed: 11207555]

196. Zheng B, He A, Gan M, et al. MIC6 associates with aldolase in host cell invasion by *Toxoplasma gondii*. *Parasitol Res.* 2009; 105:441–445. [PubMed: 19308454]
197. Kessler H, Herm-Götz A, Hegge S, et al. Microneme protein 8--a new essential invasion factor in *Toxoplasma gondii*. *J Cell Sci.* 2008; 121:947–956. [PubMed: 18319299]
198. Alexander DL, Mital J, Ward GE, et al. Identification of the moving junction complex of *Toxoplasma gondii*: a collaboration between distinct secretory organelles. *PLoS Pathog.* 2005; 1:e17. [PubMed: 16244709]
199. Straub KW, Cheng SJ, Sohn CS, Bradley PJ. Novel components of the Apicomplexan moving junction reveal conserved and coccidia-restricted elements. *Cell Microbiol.* 2009; 11:590–603. [PubMed: 19134112]
200. Besteiro S, Michelin A, Poncet J, et al. Export of a *Toxoplasma gondii* rhoptry neck protein complex at the host cell membrane to form the moving junction during invasion. *PLoS Pathog.* 2009; 5:e1000309. [PubMed: 19247437]
201. Lamarque MH, Papoin J, Finizio A-L, et al. Identification of a new rhoptry neck complex RON9/RON10 in the Apicomplexa parasite *Toxoplasma gondii*. *PLoS ONE.* 2012; 7:e32457. [PubMed: 22427839]
202. Gonzalez V, Combe A, David V, et al. Host cell entry by apicomplexa parasites requires actin polymerization in the host cell. *Cell Host Microbe.* 2009; 5:259–272. [PubMed: 19286135]
203. Sweeney KR, Morrisette NS, LaChapelle S, Blader IJ. Host cell invasion by *Toxoplasma gondii* is temporally regulated by the host microtubule cytoskeleton. *Eukaryotic Cell.* 2010; 9:1680–1689. [PubMed: 20435700]
204. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. *Cell.* 2006; 124:755–766. [PubMed: 16497586]
205. Riglar DT, Richard D, Wilson DW, et al. Super-resolution dissection of coordinated events during malaria parasite invasion of the human erythrocyte. *Cell Host Microbe.* 2011; 9:9–20. [PubMed: 21238943]
206. Waters AP, Thomas AW, Deans JA, et al. A merozoite receptor protein from *Plasmodium knowlesi* is highly conserved and distributed throughout *Plasmodium*. *J Biol Chem.* 1990; 265:17974–17979. [PubMed: 2211675]
207. Gaffar FR, Yatsuda AP, Franssen FFJ, de Vries E. Erythrocyte invasion by *Babesia bovis* merozoites is inhibited by polyclonal antisera directed against peptides derived from a homologue of *Plasmodium falciparum* apical membrane antigen 1. *Infect Immun.* 2004; 72:2947–2955. [PubMed: 15102807]
208. Hehl AB, Lekutis C, Grigg ME, et al. *Toxoplasma gondii* homologue of plasmodium apical membrane antigen 1 is involved in invasion of host cells. *Infect Immun.* 2000; 68:7078–7086. [PubMed: 11083833]
209. Richard D, MacRaild CA, Riglar DT, et al. Interaction between *Plasmodium falciparum* apical membrane antigen 1 and the rhoptry neck protein complex defines a key step in the erythrocyte invasion process of malaria parasites. *J Biol Chem.* 2010; 285:14815–14822. [PubMed: 20228060]
210. Hodder AN, Crewther PE, Anders RF. Specificity of the protective antibody response to apical membrane antigen 1. *Infect Immun.* 2001; 69:3286–3294. [PubMed: 11292751]
211. Harris KS, Casey JL, Coley AM, et al. Rapid optimization of a peptide inhibitor of malaria parasite invasion by comprehensive N-methyl scanning. *J Biol Chem.* 2009; 284:9361–9371. [PubMed: 19164290]
212. Harris KS, Casey JL, Coley AM, et al. Binding hot spot for invasion inhibitory molecules on *Plasmodium falciparum* apical membrane antigen 1. *Infect Immun.* 2005; 73:6981–6989. [PubMed: 16177378]
213. Blackman MJ, Heidrich HG, Donachie S, et al. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. *J Exp Med.* 1990; 172:379–382. [PubMed: 1694225]
214. Blackman MJ. Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. *Curr Drug Targets.* 2000; 1:59–83. [PubMed: 11475536]

215. Howell SA, Hackett F, Jongco AM, et al. Distinct mechanisms govern proteolytic shedding of a key invasion protein in apicomplexan pathogens. *Mol Microbiol.* 2005; 57:1342–1356. [PubMed: 16102004]
216. Howell SA, Withers-Martinez C, Kocken CH, et al. Proteolytic processing and primary structure of *Plasmodium falciparum* apical membrane antigen-1. *J Biol Chem.* 2001; 276:31311–31320. [PubMed: 11399764]
217. Green JL, Hinds L, Grainger M, et al. *Plasmodium* thrombospondin related apical merozoite protein (PTRAMP) is shed from the surface of merozoites by PfSUB2 upon invasion of erythrocytes. *Mol Biochem Parasitol.* 2006; 150:114–117. [PubMed: 16879884]
218. Fleck SL, Birdsall B, Babon J, et al. Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite *Plasmodium falciparum*. *J Biol Chem.* 2003; 278:47670–47677. [PubMed: 13679371]
219. Dutta S, Haynes JD, Barbosa A, et al. Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of *Plasmodium falciparum*. *Infect Immun.* 2005; 73:2116–2122. [PubMed: 15784553]
220. Harris PK, Yeoh S, Dluzewski AR, et al. Molecular identification of a malaria merozoite surface sheddase. *PLoS Pathog.* 2005; 1:241–251. [PubMed: 16322767]
221. Howell SA, Well I, Fleck SL, et al. A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage. *J Biol Chem.* 2003; 278:23890–23898. [PubMed: 12686561]
222. O'Donnell RA, Hackett F, Howell SA, et al. Intramembrane proteolysis mediates shedding of a key adhesin during erythrocyte invasion by the malaria parasite. *J Cell Biol.* 2006; 174:1023–1033. [PubMed: 17000879]
223. Baker RP, Wijetilaka R, Urban S. Two *Plasmodium* rhomboid proteases preferentially cleave different adhesins implicated in all invasive stages of malaria. *PLoS Pathog.* 2006; 2:e113. [PubMed: 17040128]
224. Buguliskis JS, Brossier F, Shuman J, Sibley LD. Rhomboid 4 (ROM4) affects the processing of surface adhesins and facilitates host cell invasion by *Toxoplasma gondii*. *PLoS Pathog.* 2010; 6:e1000858. [PubMed: 20421941]
225. Cowman AF. Mechanisms of drug resistance in malaria. *Aust N Z J Med.* 1995; 25:837–844. [PubMed: 8770361]
226. Agnandji ST, Lell B, Soulanoudjingar SS, et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. *N Engl J Med.* 2011; 365:1863–1875. [PubMed: 22007715]
227. RTS,S Clinical Trials Partnership. Agnandji ST, Lell B, et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. *N Engl J Med.* 2012; 367:2284–2295. [PubMed: 23136909]
228. Yadava A, Sattabongkot J, Washington MA, et al. A novel chimeric *Plasmodium vivax* circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. *Infect Immun.* 2007; 75:1177–1185. [PubMed: 17158893]
229. Lopez-Perez M, Villasis E, Machado RLD, et al. *Plasmodium falciparum* field isolates from South America use an atypical red blood cell invasion pathway associated with invasion ligand polymorphisms. *PLoS ONE.* 2012; 7:e47913. [PubMed: 23118907]
230. Williams AR, Douglas AD, Miura K, et al. Enhancing blockade of *Plasmodium falciparum* erythrocyte invasion: assessing combinations of antibodies against PfrH5 and other merozoite antigens. *PLoS Pathog.* 2012; 8:e1002991. [PubMed: 23144611]
231. Withers-Martinez C, Suarez C, Fulle S, et al. *Plasmodium* subtilisin-like protease 1 (SUB1): insights into the active-site structure, specificity and function of a pan-malaria drug target. *Int J Parasitol.* 2012; 42:597–612. [PubMed: 22543039]
232. Li X, Chen H, Oh SS, Chishti AH. A Presenilin-like protease associated with *Plasmodium falciparum* micronemes is involved in erythrocyte invasion. *Mol Biochem Parasitol.* 2008; 158:22–31. [PubMed: 18160114]
233. Ejigiri I, Ragheb DRT, Pino P, et al. Shedding of TRAP by a rhomboid protease from the malaria sporozoite surface is essential for gliding motility and sporozoite infectivity. *PLoS Pathog.* 2012; 8:e1002725. [PubMed: 22911675]

234. Brossier F, Starnes GL, Beatty WL, Sibley LD. Microneme rhomboid protease TgROM1 is required for efficient intracellular growth of *Toxoplasma gondii*. *Eukaryotic Cell*. 2008; 7:664–674. [PubMed: 18310358]
235. Parthasarathy S, Fong MY, Ramaswamy K, Lau YL. Protective Immune Response in BALB/c Mice Induced by DNA Vaccine of the ROP8 gene of *Toxoplasma gondii*. *Am J Trop Med Hyg*. 2013
236. Yan H-K, Yuan Z-G, Song H-Q, et al. Vaccination with a DNA vaccine coding for perforin-like protein 1 and MIC6 induces significant protective immunity against *Toxoplasma gondii*. *Clin Vaccine Immunol*. 2012; 19:684–689. [PubMed: 22379063]
237. Lourenço EV, Bernardes ES, Silva NM, et al. Immunization with MIC1 and MIC4 induces protective immunity against *Toxoplasma gondii*. *Microbes Infect*. 2006; 8:1244–1251. [PubMed: 16616574]

Figure 1.

Figure 2.

Figure 3.